| dc.contributor |
Epicentre, Paris, France. fchecci@epicentre.msf.org |
|
| dc.creator |
Checchi, F |
|
| dc.creator |
Piola, P |
|
| dc.creator |
Kosack, C |
|
| dc.creator |
Ardizzoni, E |
|
| dc.creator |
Klarkowski, D |
|
| dc.creator |
Kwezi, E |
|
| dc.creator |
Priotto, G |
|
| dc.creator |
Balkan, S |
|
| dc.creator |
Bakyaita, N |
|
| dc.creator |
Brockman, A |
|
| dc.creator |
Guthmann, J P |
|
| dc.date |
2004-04 |
|
| dc.date.accessioned |
2017-01-31T07:09:08Z |
|
| dc.date.available |
2017-01-31T07:09:08Z |
|
| dc.identifier |
Antimalarial efficacy of sulfadoxine-pyrimethamine, amodiaquine and a combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda. 2004, 9 (4):445-50 Trop. Med. Int. Health |
|
| dc.identifier |
1360-2276 |
|
| dc.identifier |
15078262 |
|
| dc.identifier |
10.1111/j.1365-3156.2004.01217.x |
|
| dc.identifier |
http://hdl.handle.net/10144/16894 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/16894 |
|
| dc.identifier |
Tropical Medicine & International Health |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/16894 |
|
| dc.description |
We report below an in vivo antimalarial efficacy study conducted in 2002 in Bundi Bugyo, a district of western Uganda housing a large displaced population. We tested sulfadoxine-pyrimethamine (SP), amodiaquine (AQ) and the combination chloroquine plus SP (CQ + SP). A total of 268 children with uncomplicated Plasmodium falciparum malaria were followed-up for 28 days according to WHO recommendations, with PCR genotyping to distinguish late recrudescences from re-infections. PCR-adjusted failure proportions at day 28 were 37.0% (34/92, 95% CI 27.1-47.7) in the SP group, 20.6% (14/68, 95% CI 11.7-32.1) in the AQ group and 22.8% (18/79, 95% CI 14.1-33.6) in the CQ + SP group. Early failures were particularly frequent in the SP group (15.2%). Clearance of gametocytes was slower in the SP and CQ + SP groups than in the AQ group. This study suggests that, in Bundi Bugyo, CQ + SP (Uganda's first-line regimen) will need to be replaced by a more efficacious regimen. Across Uganda, the deployment of SP containing combinations may not be a feasible long-term strategy. For Bundi Bugyo, we recommend a combination of artesunate and AQ. Our study also confirms previous findings that resistance is considerably underestimated by 14-day follow-ups. Antimalarial policy decisions should therefore be based on 28-day studies, with PCR adjustment to distinguish re-infections. |
|
| dc.language |
en |
|
| dc.publisher |
Wiley-Blackwell |
|
| dc.relation |
http://www.blackwell-synergy.com/loi/tmi |
|
| dc.rights |
Archived on this site with the kind permission of Wiley-Blackwell |
|
| dc.title |
Antimalarial efficacy of sulfadoxine-pyrimethamine, amodiaquine and a combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda. |
|